We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$44.5B
AUM Growth
-$1.18B
(-2.6%)
Cap. Flow
-$4.15B
Cap. Flow
% of AUM
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
9.83%
Holding
3,927
New
652
Increased
690
Reduced
847
Closed
1,056
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$309M |
| 2 |
ExxonMobil
XOM
|
+$302M |
| 3 |
Amazon
AMZN
|
+$291M |
| 4 |
Citigroup
C
|
+$253M |
| 5 |
Shopify
SHOP
|
+$238M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$383M |
| 2 |
Johnson & Johnson
JNJ
|
+$312M |
| 3 |
JPMorgan Chase
JPM
|
+$285M |
| 4 |
AT&T
T
|
+$191M |
| 5 |
Dollar General
DG
|
+$187M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.63% |
| 2 | Financials | 15.61% |
| 3 | Technology | 14.28% |
| 4 | Consumer Discretionary | 13.21% |
| 5 | Industrials | 5.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2551
Hydrofarm Holdings
HYFM
$2.66M
| $289K | ﹤0.01% |
+18,638
| New | +$426K |
|
2552
Toast
TOST
$18.9B
| $289K | ﹤0.01% |
16,014
-1,103,939
| -99% | -$20.7M |
|
|
CAJ
2553
DELISTED
Canon, Inc.
CAJ
| $286K | ﹤0.01% |
+13,200
| New | +$294K |
|
2554
Grab
GRAB
$13.7B
| $285K | ﹤0.01% |
88,400
-81,782
| -48% | -$234K |
|
2555
Itron
ITRI
$4.48B
| $284K | ﹤0.01% |
+5,615
| New | +$277K |
|
2556
Universal Corp
UVV
$1.37B
| $284K | ﹤0.01% |
+5,377
| New | +$280K |
|
|
BNT
2557
Brookfield Wealth Solutions
BNT
$11.7B
| $283K | ﹤0.01% |
+13,557
| New | +$361K |
|
2558
QuidelOrtho
QDEL
$1.13B
| $283K | ﹤0.01% |
+3,300
| New | +$280K |
|
2559
S&T Bancorp
STBA
$1.9B
| $281K | ﹤0.01% |
+8,228
| New | +$288K |
|
|
RCM
2560
DELISTED
R1 RCM Inc. Common Stock
RCM
| $278K | ﹤0.01% |
+25,400
| New | +$322K |
|
2561
Hovnanian Enterprises
HOV
$779M
| $278K | ﹤0.01% |
6,600
-9,100
| -58% | -$386K |
|
2562
PPG Industries
PPG
$24.9B
| $277K | ﹤0.01% |
2,200
-124,130
| -98% | -$15.2M |
|
|
BCYC
2563
Bicycle Therapeutics
BCYC
$269M
| $274K | ﹤0.01% |
9,271
| – | – |
|
2564
Pulmonx
LUNG
$52.8M
| $274K | ﹤0.01% |
+32,481
| New | +$309K |
|
2565
ARS Pharmaceuticals
SPRY
$579M
| $273K | ﹤0.01% |
+32,011
| New | +$208K |
|
|
KBAL
2566
DELISTED
Kimball International
KBAL
| $271K | ﹤0.01% |
+41,678
| New | +$285K |
|
2567
VanEck Junior Gold Miners ETF
GDXJ
$6.86B
| $271K | ﹤0.01% |
+7,599
| New | +$250K |
|
2568
Weyerhaeuser
WY
$17.6B
| $270K | ﹤0.01% |
+8,700
| New | +$270K |
|
|
CTLP
2569
DELISTED
Cantaloupe
CTLP
| $268K | ﹤0.01% |
61,494
-210,186
| -77% | -$745K |
|
2570
Zai Lab
ZLAB
$2.07B
| $267K | ﹤0.01% |
8,710
| – | – |
|
2571
Equinor
EQNR
$97.3B
| $265K | ﹤0.01% |
7,400
-2,000
| -21% | -$71.8K |
|
2572
Vanguard International Dividend Appreciation ETF
VIGI
$9.01B
| $265K | ﹤0.01% |
+3,800
| New | +$256K |
|
2573
Applovin
APP
$134B
| $264K | ﹤0.01% |
25,090
-121,004
| -83% | -$1.77M |
|
2574
Rocket Pharmaceuticals
RCKT
$343M
| $264K | ﹤0.01% |
13,500
-88,356
| -87% | -$1.63M |
|
|
MTA
2575
Metalla Royalty & Streaming
MTA
$689M
| $263K | ﹤0.01% |
+53,660
| New | +$257K |
|
Similar funds
Marshall Wace's Q4 2022 Portfolio in Review
As of Q4 2022, Marshall Wace held 3,927 positions worth $44.5B, down 2.6% from $45.6B the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.
Marshall Wace withdrew a net $4.15B in Q4 2022, closing 1,056 positions and reducing 847 holdings. Its most notable exit was Humana, an estimated $383M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Financials and Technology.
Against the trend, Marshall Wace opened a new position in Elevance Health worth $188M.
- Marshall Wace's largest Q4 2022 buy was Elevance Health: 366,649 shares worth $188M.
- Marshall Wace added most to Biogen in Q4 2022, an estimated $309M increase.
- Marshall Wace's biggest Q4 2022 reduction was Johnson & Johnson, cutting an estimated $312M.
- Marshall Wace fully exited Humana in Q4 2022, selling an estimated $383M.
- Marshall Wace's ten largest holdings make up 9.8% of its $44.5B portfolio in Q4 2022.
- Marshall Wace opened 652 new positions and closed 1,056 in Q4 2022.
- Marshall Wace's portfolio value fell 2.6% quarter-over-quarter to $44.5B.
Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.